Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2026.05.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Jodi Lipof und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, Immunotherapy, Adoptive. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Kite Pharma Inc.
Abstract (Originalsprache)
BACKGROUND: CAR T-cell therapies and bispecific antibodies (BsAb) are increasingly used in 4L+ relapsed/refractory multiple myeloma (RRMM), but long-term data to inform optimal sequencing are limited. OBJECTIVE: To estimate progression-free survival (PFS), overall survival (OS), and costs associated with CAR T followed by BsAb versus BsAb followed by CAR T in 4L+ RRMM. STUDY DESIGN: A US-based Markov model with time-dependent transitions and a 10-year time horizon compared the two treatment sequences. PFS and OS for starting treatments were sourced from clinical trials; subsequent treatment outcomes were derived from meta-analyses of clinical trials and real-world studies. Probabilistic sensitivity analyses (1,000 simulations) estimated 95% credible ranges. Total costs were calculated using published literature. RESULTS: CAR T before BsAb resulted in significantly longer survival versus BsAb before CAR T: median PFS 46.4 months (95% CI, 38.3-54.5) vs. 16.8 months (95% CI, 13.2-18.6) (HR 0.36 [95% CI 0.27-0.44]); median OS 61.5 months (95% CI, 53.8-69.9) vs. 32.0 months (95% CI, 13.2-44.5) (HR 0.52 [95% CI 0.26-0.91]). Total 10-year costs were $1,019,513 (95% CI, $934,974-1,105,472) vs. $1,450,958 (95% CI, $1,229,401-1,544,828), yielding cost savings of $431,445 (95% CI, $185,905-556,259). CONCLUSION: In this simulation model, using CAR T before BsAb in 4L+ RRMM significantly reduced risk of progression or death by 64%, death by 48%, and lowered overall cost of care versus BsAb before CAR T. These findings support the use of CAR T before BsAb in 4L+ RRMM to improve long-term patient outcomes with substantial cost savings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA.
- Curta Inc., Seattle, WA.
- Arcellx Inc., Redwood City, CA.
- Kite, a Gilead Company, Santa Monica, CA.
- Curta Inc., Seattle, WA. Electronic address: cynthia.gong@curta.com.
Förderung
- Kite Pharma Inc
Zitieren
APA
Lipof, J., Bloudek, B., Ray, A., Ting, J., Hasegawa, K., Gong, C., Williams, T., Ramsey, S., & Chari, A. (2026). Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.05.014
Vancouver
Lipof J, Bloudek B, Ray A, Ting J, Hasegawa K, Gong C, et al. Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.05.014
BibTeX
@article{Lipof2026,
author = {Lipof, Jodi and Bloudek, Brian and Ray, Avik and Ting, Jie and Hasegawa, Ken and Gong, Cynthia and Williams, Troy and Ramsey, Scott and Chari, Ajai},
title = {Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.05.014}
}
EUVIMED